See where GLP, GCP, and GCLP apply in drug development & use our decision framework to select the right-fit compliance.
How next-gen mass spec FFPE proteomics enables retrospective discovery in archived tissue, unlocking new biomarkers & targets.
Turning normal tissue biology from a late-discovered liability into an early part of target evaluation.
Tackling the skepticism that comes with multi-omics initiatives and how to answer, what do we actually do with this data?
On the use of comprehensive tumor proteomics to identify cancer targets and biology hiding beyond DNA and RNA.
Uncovering meaningful physiological differences among patients who appear similar by diagnosis or lab values.
Quantify specific proteins with sequence-confirmed accuracy – without the antibody limitations of ELISA.
Directly measuring the layers of functional tumor biology that shape how a tumor behaves and responds to treatment.
Exploring why, to fully understand systemic pathology of rare diseases, we must look beyond genetic sequence alone.
Mapping pathway‑level mechanisms & molecular drivers behind signatures observed via high-content imaging.
On closing the gap between molecular measurement & clinical meaning, rapidly extracting actionable biological signals.
PharmaShots delves into Sapient’s mission to transform multi-omics research through innovation & world-class partnerships.
"*" indicates required fields
